Previous 10 | Next 10 |
New Zealand Ministry of Health announced aggressive measures to reduce smoking, including a reduced nicotine mandate by 2025 22nd Century fully engaged and ready to support New Zealand’s government as it takes bold steps to make country smokefree by 2025 BUF...
High on Growth: Cannabis REITs are far-and-away the best-performing REIT sector of the past half-decade as the budding industry thrives in the murky and often contradictory regulatory framework of legalized marijuana. Joining Innovative Industrial, Power REIT, and AFC Gamma, a pair of...
Richard Fitzgerald Joins as Chief Financial Officer John Franzino Transitions to Chief Administrative Officer BUFFALO, N.Y., Nov. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading agricultural biotechnology company focused on tobacco ...
The healthcare industry has been in investors’ crosshairs since the onset of the COVID-19 pandemic last year, thanks to its role in helping the world fight the virus. Moreover, massive investment in the industry for the discovery and manufacture of viable therapies for several critical...
Califf Is a Longtime Proponent of Tobacco Control; Indicated Nicotine Mandate Should Be Key Priority For FDA MRTP Authorization And Launch of VLN ® Will Serve as Vanguard for FDA’s Proposed Nicotine Cap BUFFALO, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- 22n...
During the semiannual review, Clovis Oncology (NASDAQ:CLVS), Maastercraft Boat (NASDAQ:MCFT), Asana (NYSE:ASAN), Five9 (NASDAQ:FIVN), Upstart (NASDAQ:UPST), Passage Bio (OTC:PBIO), American Vanguard (NYSE:AVD), Brightcove (NASDAQ:BCOV), 22nd Century (NASDAQ:XXII) and Duluth (NASDAQ:DLTH) ...
MSCI will be including total 112 companies including Zomedica (NYSE:ZOM), Clovis Oncology (NASDAQ:CLOV), 22nd Century (NASDAQ:XXII), Omeros (NASDAQ:OMER) and Verastem (NASDAQ:VSTM) in its MSCI US Micro Cap Index as a part of Semi-Annual Index Review. MSCI excluded a...
During the semi-annual review, Clovis Oncology (CLVS -1.1%), 22nd Century Group (XXII -1.2%), Verastem (VSTM +8.7%), Omeros (OMER -0.7%), Therapeutics MD (TXMD -3.2%), CEL-SCI (CVM +2.1%), ZIOPHARM Oncology (ZIOP -1.9%), Karyopharm Therapeutics (KPTI +1.1%), Esperion Therapeutics (E...
BUFFALO, N.Y., Nov. 11, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through plant science, today announced that the Company ...
22nd Century Group, Inc. (XXII) Q3 2021 Earnings Conference Call November 4, 2021 10:00 AM ET Company Participants Mei Kuo – Director-Communications and Investor Relations Jim Mish – Chief Executive Officer Mike Zercher – President and Chief Operating Officer John Franzin...
News, Short Squeeze, Breakout and More Instantly...
22nd Century Group Inc Company Name:
XXII Stock Symbol:
NYSE Market:
22nd Century Group Inc Website:
Patented, Fully Water Dispersing, Biodegradable Solution for World's Most Littered Item Mocksville, North Carolina--(Newsfile Corp. - July 10, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announce...
Mocksville, North Carolina--(Newsfile Corp. - July 9, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announced a new agreement for full-scale commercial rollout of its VLN® reduced nicotine cont...
Mocksville, North Carolina--(Newsfile Corp. - June 25, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announced a $1.5 million reduction in its secured debt via a paydown of the GVB secured promissor...